State coverage
Pennsylvania Medicaid and GLP-1 coverage
Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Coverage for overweight and obesity ended January 1, 2026. Saxenda is no longer covered for anything.
- Appeal deadline
- 30 days from written notice (60 days where no written notice was required) source
- Date read
- August 2026
Pennsylvania ended coverage of GLP-1 drugs for overweight and obesity on January 1, 2026, by bulletin. If you need the citable document — the thing a reporter or a benefits counselor actually has to produce — it is Medical Assistance Bulletin dated November 24, 2025, signed by the Deputy Secretary of the Office of Medical Assistance Programs, and the state republished the change as a formal notice in the Pennsylvania Bulletin a month later.
Two details in that bulletin get lost in summaries of it. Saxenda was not merely dropped for obesity; the state says it is no longer covered for any indication at all. And obesity drugs that are not GLP-1s stayed covered, with the preferred ones available without prior authorization — so "Pennsylvania dropped weight-loss coverage" is not quite what the document says.
The bulletin also answers the managed care question directly, which is unusual and useful: the medical-necessity guidelines are used in the fee-for-service and managed care delivery systems alike. Your HealthChoices plan does not get to reach a different answer, though the bulletin notes the procedure for requesting authorization may differ, so ask your own plan how to file.
What we could verify for Pennsylvania
The state's own words, effective January 1, 2026: "drugs containing a GLP-1 receptor agonist will not be covered for the treatment of overweight or obesity. Drugs containing a GLP-1 receptor agonist will continue to be covered for all other medically accepted indications with a prior authorization. Saxenda (liraglutide) will no longer be covered for any indication."
Pennsylvania Department of Human Services, Office of Medical Assistance Programs, effective January 2026 · source
Obesity drugs that do not contain a GLP-1 stayed on. The bulletin says they "will continue to be covered by the MA Program," and that the ones marked preferred on the statewide list are available without prior authorization, naming phentermine capsules and tablets, so long as quantity limits are not exceeded.
Pennsylvania Department of Human Services, Office of Medical Assistance Programs, effective January 2026 · source
Being in a managed care plan does not change the answer. The bulletin states that the guidelines used to decide medical necessity for these drugs "will be utilized in the fee-for-service and managed care delivery systems," and tells enrollees in managed care to take questions about how to request prior authorization to their own plan.
Pennsylvania Department of Human Services, Office of Medical Assistance Programs, effective January 2026 · source
The change also ran as a formal state notice, which is the version to cite if you need one in the public record: "Medical Assistance Program Compensable Service Change: GLP-1 Drugs to Treat Overweight and Obesity," 55 Pa.B. 8828, published Saturday, December 27, 2025, announcing discontinuation "effective for dates of service on and after January 1, 2026."
Pennsylvania Bulletin, Department of Human Services, effective December 2025 · source
Pennsylvania's appeal window is shorter than the federal ceiling, and this is the one number on this page worth writing down. The state regulation gives you "Thirty days from the date of written notice of a decision or action," and 60 days where no written notice was required or sent. Appeals filed late "will be dismissed without a hearing." A separate 6-month window applies where the agency failed to send a required notice or made an administrative error.
55 Pa. Code §275.3, Pennsylvania Code, effective December 1980 · source
Pennsylvania is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. Pennsylvania Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Pennsylvania with the rest in the coverage matrix.
Regional insurers that sell plans in Pennsylvania and have their own page here, quoted from their own policy documents: Highmark Blue Cross Blue Shield and Independence Blue Cross. The national insurers are on the insurance index.
If you work for the State of Pennsylvania
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: Pennsylvania Employees Benefit Trust Fund (PEBTF). Its pharmacy benefit runs through CVS Caremark.
Weight-loss drugs excluded
The PEBTF's 2026 plan description excludes medications for weight reduction, including ones approved for other uses. It points members to a CVS discount program for drugs the plan doesn't cover.
Prescription plan exclusions: "Medications for weight reduction, including weight reduction medications approved or prescribed for other indications".
PEBTF, Summary Plan Description 2026, effective January 2026 · source
The medical exclusions cover obesity treatment, with an exception for "eligible services and supplies with respect to a weight management program approved by the PEBTF".
PEBTF, Summary Plan Description 2026, effective January 2026 · source
"Beginning on April 1, 2026, you can save on medications that aren't covered under your PEBTF Prescription Drug Plan. You will save up to 85% on generic medications and up to 37% on brand-name medications with CVS Caremark's RxSavingsPlus."
PEBTF, Prescription Drug Plan (active members) · source
If the appeal fails, or you cannot wait
Pennsylvania Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerCoreAge RxCheck availability | Compounded semaglutide advertised at $99 a month at every dose. The page our link opens has shown $149 instead, and a consultation fee can be added that may not be refundable. |
| PartnerOakCheck availability | One flat price at every dose, with shipping and supplies included free. |
| PartnerGala HealthCheck availability | One price at every dose. The advertised rate needs a yearly subscription. |
| PartnerDirect MedsCheck availability | One price at every dose from $147, with no monthly membership. The page states its discount two ways ($150 off in the banner, up to $200 off on the tiles), so check the total at checkout. |
| PartnerFoundCheck availability | Bills clinician visits to your insurance where it's in network, with the drug charged separately. Its Medicare offer, brand GLP-1s from $50 a month, doesn't count toward your Part D deductible or out-of-pocket maximum, and Extra Help doesn't apply. |
| PartnerEdenCheck availability | Semaglutide at $99 a month at every dose, with no membership on the page our link opens. Eden's own site pairs the same $99 with a required membership ($39 the first month, then $99), so check which one you're signing up for. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in August 2026 and September 2026, and they change often. Check the current number before you buy.
Where this comes from
- Pennsylvania Department of Human Services, Office of Medical Assistance Programs, effective January 2026 — www.pa.gov/content/dam/copapwp-pagov/en/dhs/documents/docs/publications/
- Pennsylvania Bulletin, Department of Human Services, effective December 2025 — www.pacodeandbulletin.gov/Display/pabull?file=/secure/pabulletin/data/vo
- 55 Pa. Code §275.3, Pennsylvania Code, effective December 1980 — www.pacodeandbulletin.gov/Display/pacode?file=/secure/pacode/data/055/ch